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ABSTRACT
Local anesthetic systemic toxicity (LAST) is a rare complication of administering
local anesthetic medications. However, this complication is potentially deadly, especially
without prompt and correct treatment. Due to the rarity of LAST and the fact that its
treatment differs from the conventional treatment of cardiac arrest, the authors sought a
best practice recommendation to guide its treatment. While the most effective treatment
for LAST has been well established, a thorough review of literature and survey of clinical
preceptors demonstrated that most providers have not encountered LAST in clinical
practice. Additionally, lipid emulsion therapy is a somewhat controversial treatment
amongst some providers, even though its effectiveness is well documented.
This doctoral project sought to develop a best practice recommendation to guide
the treatment of LAST events and increase the confidence of providers in their ability to
recognize and treat LAST. The recommendation was developed after a thorough review
of the literature. The information was used to create a report of findings that were
presented to a panel of experts. Feedback from the expert panel revealed that the
respondents have not encountered a LAST event in their clinical practice. They all
agreed that this practice recommendation would potentially help to guide the correct
treatment of LAST. Their feedback, along with the report of findings was subsequently
used to develop an executive review that was sent to a hospital affiliated with the Nurse
Anesthesia Program at The University of Southern Mississippi in which the evaluation
was performed. The executive summary also included an education module for the
anesthesia staff.
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CHAPTER I - INTRODUCTION
Local anesthetic systemic toxicity (LAST) is a rare, but potentially fatal
complication of administering local anesthetic medications. LAST can quickly lead to
the central nervous system and cardiac compromise (Tetzlaff, 2000). LAST treatment
differs in a few key areas from conventional treatment of cardiac arrest and, therefore,
should be approached in a different, more precise manner (Dillane & Finucane, 2009).
For example, calcium channel blockers and lidocaine are commonly used to treat
arrhythmias that arise in a patient with cardiac compromise (Tetzlaff, 2000). However,
these medications will lead to a further decline in the patient experiencing a LAST event.
While the most effective treatment for LAST has been well established, both review of
literature and survey of clinical preceptors have shown that its rarity makes it a condition
that most providers have not encountered in clinical practice (Manavi, 2010; Nedialkov,
Umadhav, Valdes, & Campbell, 2018). According to a 2012 study, “the incidence (per
1000 blocks) of adverse events across all peripheral regional anesthetics was 1.8 (95%
confidence interval [CI]” (Sites, Taenzer, Herrick, & Gilloon, 2012, p. 478).
Additionally, lipid emulsion has been shown to drastically improve resuscitation
following local anesthetic systemic toxicity although its use remains controversial among
anesthesia providers (Nedialkov et al., 2018).
Problem Description
The operating room is a dynamic healthcare practice setting. Due to this everchanging environment, crises dictate a rapid response from healthcare professionals. The
occurrence of LAST is rare (Sites et al., 2012). Failure to treat or incorrect treatment of
LAST has the potential to result in patient injury or death (Barash et al., 2017). A review
1

of the literature and informal interviews with anesthesia providers revealed that a
knowledge deficit exists surrounding the treatment of LAST (Corcoran et al., 2006, p.
1324-1325; Appendix A). Potential negative consequences of the failure to manage
LAST include central nervous system (CNS) toxicity, cardiac toxicity, and death (Dillane
& Finucane, 2009). To address this gap in knowledge, a best practice recommendation
was compiled based on current evidence-based literature. The best practice
recommendation was further used to create a treatment protocol that was presented to
anesthesia administration at a University of Southern Mississippi (USM) clinical affiliate
hospital, along with an educational tool that can be used for certified registered nurse
anesthetist (CRNA) education of the proposed protocol.
Available Knowledge
Local Anesthetics
Local anesthetics are medications used to stop the transmission of pain sensation
by blocking the conduction of nerve impulses along nerve fibers (Lin & Liu, 2017, p.
564). To understand the pharmacodynamics of local anesthetics, one must have a basic
knowledge of nerve conduction. The transmission of a nerve impulse relies on the
existence of an electrical gradient across the nerve cell membrane. This gradient is
established by the influx and efflux of sodium and potassium ions. The propagation of a
nerve impulse begins when a sufficient electrical stimulus causes a change in the
membrane potential to the level of threshold potential. This phenomenon leads to
depolarization, which is a rapid influx of sodium ions through a voltage-gated sodium
channel from the extracellular to the intracellular space. This voltage-dependent gate is
located on the intracellular portion of the cell membrane. Local anesthetics work by
2

reversibly inhibiting the influx of sodium through these voltage-gated sodium channels,
preventing the transmission of pain signals (Lin & Liu, 2017).
Benefits of Local Anesthetics Use in Anesthesia Practice
Neuraxial Anesthesia
Many studies have focused on the differences in morbidity and mortality
following surgical procedures using general vs neuraxial anesthesia. A meta-analysis
including over 3,000 patients found that neuraxial anesthesia (subarachnoid and epidural
anesthesia) was associated with a low risk of death in the 30 days immediately following
surgery (Barash et al., 2017). Neuraxial anesthesia was also found to decrease the risk of
post-operative pneumonia. Another meta-analysis involving over 18,000 patients who
had undergone surgery to treat hip fracture found that the use of neuraxial anesthesia was
associated with decreased intra-hospital death and pulmonary complications (Barash et
al., 2017).
Neuraxial anesthesia has also shown improved outcomes in specific patient
populations. A small single-institution study found decreased postoperative pulmonary
complications, arrhythmias, and shorter stays in intensive care for patients following
lower extremity amputations when regional anesthesia was used instead of general
anesthesia (Barash et al., 2017). Regional anesthesia has also been associated with
decreased respiratory events in patients with chronic obstructive pulmonary disease
(COPD), a condition that is known to cause complications in general anesthetics. A
study of more than 14,000 patients undergoing knee arthroplasty found fewer wound
infections, pneumonia, infections, and blood transfusions following regional anesthesia in
comparison to general anesthesia (Barash et al., 2017). This same study also found a
3

shorter period of hospital stay for those patients who received neuraxial anesthesia.
Interestingly, epidural anesthesia may be associated with an increased survival rate
following cancer surgeries. The improved summary is attributed to the avoidance of
immunosuppression that can occur with the use of general anesthesia and postoperative
opioids (Barash et al., 2017). Epidural and spinal anesthesia are the techniques of choice
for analgesia for labor and cesarean section, due to the prevention of unwanted drug
delivery to the fetus.
Peripheral Nerve Blockade
Regional anesthesia allows the provider to administer long-acting anesthesia and
analgesia to a specific site of the body. Regional anesthetic techniques can be
implemented in a wide variety of surgical procedures. According to Barash et al. (2017),
peripheral nerve blockade can reduce mortality and morbidity, and the need for additional
surgical intervention following major surgical procedures. Peripheral nerve blockade is
also associated with greater analgesia and improved patient satisfaction. Another study
of randomized control trials demonstrated that single-shot peripheral nerve blocks were
associated with decreased pain, decreased the need for a “rescue” pain medication,
decreased nausea and vomiting, and increased patient satisfaction scores (Cousins, Carr,
Horlocker, & Bridenbaugh, 2009). Additionally, an observational study of ambulatory
patients demonstrated a 76% decrease in unplanned hospitalizations following anterior
cruciate ligament (ACL) repair surgery (Cousins et al., 2009). Continuous indwelling
peripheral nerve blocks offer the additional benefit of extending the analgesia farther into
the postoperative period (Barash et al., 2017).

4

Local Anesthetic Systemic Toxicity
LAST is a life-threatening event that results from local anesthetic reaching
significant systemic circulating levels. The symptoms of LAST most frequently appear
within the first few minutes of injection of a local anesthetic. The toxicity most likely
occurs because of inadvertent intravascular injection of local anesthetic or injection of
higher than the therapeutic dose (Barash et al., 2017). LAST symptoms occur in the
central nervous system and/or the cardiovascular system. “The effects on the CNS are
determined by the plasma concentration of the local anesthetic. At low plasma
concentration, mild disturbances to the sensory systems appear. As the plasma
concentration increases, CNS excitation and seizure activities predominate.” (Barash et
al., 2017, p. 575). Untreated, these CNS symptoms can lead to respiratory depression,
coma, and eventually death. Cardiovascular symptoms are seen at a higher plasma
concentration than that which leads to CNS symptoms (Barash et al., 2017). While all
local anesthetics can cause hypotension, dysrhythmias and myocardial depression, more
potent agents, such as bupivacaine, ropivacaine, and levobupivacaine, are predisposed to
devastating outcomes such as cardiovascular collapse and complete heart block (Barash
et al., 2017). “Surveys from France and the United States of over 280,000 cases
involving regional anesthesia show an incidence of seizures of approximately 1/10,000
with an epidural injection, and 7/10,000 with peripheral nerve blocks” (Barash et al,
2017, p. 453). This study magnifies the benefit versus risk ratio associated with regional
anesthesia.
The exact mechanism that induces LAST is not clearly understood. To quote
Clinical Anesthesia (Barash, 2017), “The underlying pathophysiology responsible for
5

local anesthetic-induced cardiovascular collapse has not been fully established” (Barash
et al., 2017, p. 576). “Local anesthetics readily cross the blood-brain barrier and, as a
result, central nervous system toxicity can occur with systemic absorption or inadvertent
intravascular injections” (Barash et al., 2017, p. 575). The ease of local anesthetic
diffusion across the blood-brain barrier explains why in some cases, confusion and
seizure activity precedes cardiovascular symptoms. An especially dangerous drug that
can present with cardiac symptoms is bupivacaine. “Bupivacaine has an inherently
greater affinity for binding resting and inactivated cardiac sodium channels than
lidocaine” (Barash et al., 2017 p. 577).
Measures to Prevent LAST
The optimal approach to treating LAST is to prevent it. Some issues with the
information on LAST treatment and prevention are associated with its infrequency and
the ethical issues of studying it. According to a 2011 National Association of
Biotechnology Information article by Sandhya Yaddanapudi (para. 2),
… providers should be aware of and adhere to maximum dose recommendations
of various local anesthetics. The current recommendations are not entirely based
on scientific evidence. They have been extrapolated from animal experiments,
case reports of LAST, and some pharmacokinetic studies because human
randomized control trials (RCT) are difficult to conduct for ethical reasons.
With the morbidity and mortality associated with LAST, every effort should be made to
prevent intravascular injection. According to the same study,
No single intervention can reliably eliminate the risk of LAST. Several steps
must be taken to avoid intravascular injection and elevated blood concentration of
6

the LA during the performance of the regional technique. Aspiration before
injection of LA and the use of an intravascular marker such as epinephrine
reduces the likelihood of accidental intravascular injection to a large extent.
(Yaddnapudi, 2011, para. 2)
The use of ultrasound-guided regional anesthesia (UGRA) is a topic that is being
explored as a best practice guideline to prevent LAST. In theory, visualization of
anatomic structures and medication spread should reduce adverse outcomes associated
with regional anesthesia, including LAST. Due to the extreme rarity of this complication,
a statistically significant difference between nerve localization techniques, if indeed any
difference exists, will likely never be realized. Evidence is conflicting regarding whether
UGRA results in true reduction of LAST (Neal & Richard, 2010).
Evidence-Based Practice for Treatment of LAST
The American Society of Regional Anesthesia and Pain Medicine (ASRA)
updated the checklist for the management of LAST as recently as 2017. The
recommendations are described as “fundamentally different from conventional
cardiopulmonary resuscitation. Insofar as toxic cardiomyopathy differs from other causes
of CV collapse” (Neal & Barrington, 2017, para. 5). These guidelines recommend early
airway support over immediate cardiac support. This approach prioritizes the prevention
of hypercarbia and subsequent acidosis that can potentiate LAST. This article states
succinctly, “Successful treatment of LAST seeks to effectively moderate or reverse the
mechanisms underlying the local anesthetic toxicity” (Neal & Barrington, 2017, para. 6).
Data retrieved from rat studies reinforce the practice of administering small doses of
epinephrine when patient condition indicates (1mcg/kg or less) (Barrington, 2017).
7

“Lipid therapy is recommended at the first sign of arrhythmia, prolonged seizures, or
rapid clinical deterioration of the patient” (Neal & Barrington, 2017, para. 8). Multiple
case reports demonstrate successful resuscitation following LAST when intralipid is used
as early treatment (Valera & Burns, 2010). However, the use of intralipid therapy
remains controversial among anesthesia providers (Nedialkov et al., 2018).
Existing Protocols
As stated before, in 2017 the ASRA updated the checklist for the treatment of
local anesthetic system toxicity treatment. Recommendations by The Association of
Anaesthetists of Great Britain and Ireland (2010) and Medscape (2019) echo the
treatment described by the ASRA. The initial treatment suggested is to stop or limit the
insulating substance and get assistance. If serious signs of LAST occur, consider lipid
emulsion therapy immediately (ASRA 2017). Due to the gravity of a cardiovascular
event from LAST, notifying the nearest cardiopulmonary bypass team is also
recommended. Providers are encouraged to ventilate with 100% oxygen, avoid
hyperventilation, and insert advanced airway if needed to control seizures.
Benzodiazepines are the preferred method of seizure management. Propofol is to be
avoided due to its cardiac depressive properties. If the patient weighs greater than 70
kilograms, a bolus of 100 milliliters 20% lipid emulsion over a 2-3-minute period is
recommended, followed by an infusion of 200-250 milliliters over 15-20 minutes. For a
patient less than 70 kilograms a bolus of 1.5 milligram/kilogram (ideal body weight) lipid
emulsion over 2-3 minutes, followed with an infusion of 0.25 milligram/kilogram is
recommended. With a dosing limit of 12 milligram/kilogram, the total volume of lipid
emulsion can approach 1 liter in a prolonged resuscitation (ASRA, 2017).
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Protocol Creation
Having standardized protocols in place for crises is imperative. The airline
industry has gained a record of safety that has become an example of success in other
professions. This success is largely attributed to protocols. Despite success in other
industries, process standardization in healthcare has been slow to gain traction or to
demonstrate a positive impact on the safety of care (Leotsakos, Zheng, & Croteau, 2014).
The human variables of practitioners and sick patients are complex and often not easily
predicted. A study in the International Journal for Quality in Health Care states, “In
health care, evidence shows that divergent patterns of care result in worse clinical
outcomes and that removal of variance can reduce risk, and costs” (Leotsakos et al.,
2014, para. 8).
Rationale
Evidence shows many benefits of local anesthetic use, including decreased length
of hospital stay, increased pain control, decreased pulmonary complications, decreased
opioid use, and even increased survival rates in some cases (Baresh et al., 2017). For
these reasons, the practice of regional anesthesia is on the rise. As with any anesthetic
procedure, risks must be acknowledged and properly managed. True local anesthetic
systemic toxicity is a rare event; thus, most anesthesia providers have not encountered it
in training or clinical practice. This inconsistency leads to a possible gap in provider
understanding of the proper treatment for LAST. Evidence shows that the use of
checklists or protocols can improve the selection of the appropriate treatment modality in
uncommonly encountered clinical events (Harrison, Manser, Howard, & Gaba, 2006;
Ziewacz, Ariaga, Bader et al., 2011). Therefore, a LAST treatment checklist was
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presented to ensure an effective treatment in the event of LAST. The evidence-based
research indicates that this protocol is readily available in all operative environments
where local anesthetics are to be administered (ASRA, 2017).
Specific Aims
From a review of the evidence and informal interviews with anesthesia providers,
the authors have found that a knowledge deficit exists surrounding the treatment of LAST
(Corcoran et al., 2006) (Appendix-C). This project aimed to develop a best practice
guideline to direct the appropriate treatment of LAST. The rarity at which LAST is
encountered in clinical practice predisposes providers to a gap in experience with its
treatment. This project aimed to bridge that gap by providing an easily accessible and
concise aid that can be readily used to guide providers in the treatment of local anesthetic
systemic toxicity. The intent is that this checklist will increase providers’ confidence in
their ability to treat LAST, encouraging local anesthetics to use in their clinical practice.
DNP Essentials
This DNP project fulfilled all eight DNP Essentials set forth by the American
Colleges of Nursing (AACN) (2006), as referenced in Appendix E. These essentials
describe the fundamental competencies that are required for advanced practice nurses.
The essentials also set forth the required elements of the curriculums of DNP programs.
Summary
Through informal interviews with anesthesia administration and CRNAs at a
USM clinical affiliate hospital, it was determined that the hospital lacked a best practice
clinical policy regarding the treatment for LAST, a rare yet potentially deadly
complication of local anesthetic administration. Therefore, available knowledge was
10

examined to determine the best practice for the treatment of LAST. The research was
consistent on the appropriate treatment for LAST (Association of Anesthetists of Great
Britain and Ireland [AAGBI], 2010; ASRA, 2017), and the American Society of Regional
Anesthesia and Pain Medicine has developed a checklist that includes the major points of
LAST treatment (ASRA, 2017).
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CHAPTER II – METHODS
Context
A current best practice investigation regarding local anesthetic systemic toxicity
was conducted at a USM affiliate hospital in Mississippi. Through informal interviews
with anesthesia administration and CRNAs and a review of literature, it was determined
that some hospitals lacked a best practice clinical policy regarding the treatment for
LAST. The 260-bed facility reported in 2016 an average total daily census of 134.6
patients. The hospital reported, 215 babies delivered in 2016 (Mississippi State
Department of Health, 2018). According to Jason Coleman, CRNA, “this hospital
provides surgical services, utilizing regional anesthesia with the administration of local
anesthetics” (J. Coleman, personal communication).
Intervention, Study of Intervention, and Measures
Upon completion of clinical rotations at various surgical facilities in Mississippi,
it was recognized that no distinct policy existed at a clinical affiliate hospital for the
treatment of local anesthetic systemic toxicity. In addition, an informal survey of
anesthesia providers demonstrated little experience with the treatment of LAST.
Therefore, available knowledge was examined and synthesized to determine the best
practice for the treatment of LAST. A literature search was performed to analyze best
practice guidelines for LAST prevention and treatment. A secondary search was done to
explore the benefits of using checklists, protocols, and/or cognitive aids in the treatment
of anesthetic emergencies. Several databases including CINAHL, Cochrane, Google
Scholar, and PubMed were used to find relevant articles. The following search terms
were used: local anesthetic systemic toxicity, LAST treatment, LAST prevention,
12

anesthesia emergency protocol, and anesthesia cognitive aids. The initial search had
limitations of publication dates between 2008 and 2018. This search resulted in 752
articles. The articles that were included in this project were chosen based on their
relevance to the topic studied. Also, leading textbooks in the field of anesthesia were
reviewed and the applicable sections selected for use in this project.
The literature review included the ASRA Checklist for Treatment of Local
Anesthetic Systemic Toxicity and evidence that supports the steps on the list. Additional
protocols by Medscape (2019) and The Association of Anaesthetists of Great Britain and
Ireland (2010) concur on the appropriate LAST treatment. These protocols, along with
the supporting peer-reviewed literature was used as a guide for the development of a
policy recommendation regarding the treatment of LAST. Once the project was approved
by the committee, it was submitted to the Institutional Review Board (IRB) with the
intention to seek exemption for this project (IRB Protocol # 19-327, Appendix A).
The available knowledge was synthesized to compile a report of findings, as
shown in Appendix C. This report of findings, along with the ASRA checklist for
treatment of local anesthetic systemic toxicity was presented to a panel of experts
(Appendix A). This panel of experts was assembled by way of face-to-face invitation.
This group of the chosen facility personnel included the Chief CRNA, a pharmacist, a
supervising registered nurse, and a health policy expert. The Chief CRNA was asked to
join the panel of experts due to his expertise in anesthesia, as well as, his familiarity with
the facility and its available resources. A pharmacist was included on the panel because
of their pharmacological expertise and their knowledge of the availability, price, and
storage requirements of medications. The panel also included a registered nurse who
13

supervises the block/preparation area, due to their knowledge of the block procedures and
the resources available in this area where local anesthetics are frequently administered.
Finally, the healthcare policy expert was included, because of her expertise and
experience with health policy creation.
An evaluation tool, shown in Appendix D, was developed by the ASRA and was
used to gather feedback on the presented data. The evaluation included the clarity of the
presented information, the quality of the information, and relevance to practice. In
addition, consideration was given to whether or not the best practice should be
implemented, a space for additional comments was provided. The feedback was
reviewed and no revisions to the policy recommendation were deemed necessary, nor to
the executive summary (Appendix F). The executive summary containing the report of
findings, the policy recommendation, and the associated educational module were then
presented to the Chief CRNA for consideration of implementation. The participants were
sent an anonymous survey link and asked not to include any identifying information on
their surveys in order to keep their comments confidential. Data was kept on a personal
password-protected laptop, and files were kept in a locked drawer. Data was retained
until project completion, then all files were permanently deleted from the storage device
and written documentation was shredded.
Analysis
Qualitative data was collected using an evaluation tool (Appendix D). The data
was gathered in a face-to-face manner along with a presentation of the policy. The
information was reviewed and entered into Table 1 where responses were given
quantitative values. The data processing was accomplished before presenting the policy
14

recommendation along with the executive summary (Appendix F) along with an
educational module for the CRNAs. Statistical analysis would have been of little value
due to the small panel of experts and was therefore not done. A quantitative analysis
from the provided feedback was performed to determine common feedback and concerns
for the adoption of this evidence-based protocol.
Table 1
Survey Questions
Questions
This best practice
recommendation was
presented clearly.
The presented
information is of high
quality.
The information is
relevant to clinical
practice.
Do you believe that
this best practice
recommendation
should be
implemented in your
facility?
Please provide any
additional comments
and/or suggestions.

Response 1

Response 2

Response 3

Strongly Agree

Strongly Agree

Strongly Agree

Strongly Agree

Strongly Agree

Strongly Agree

Strongly Agree

Strongly Agree

Strongly Agree

Yes

Yes

Yes

Add mock drills

Alternative to lipids if
unavailable to facility

None

Ethical Considerations
The ethical considerations for this project were minimally related to all presented
recommendations have been endorsed by leading anesthesia organizations and supported
by evidence-based and peer-reviewed literature. Specific concerns center around the
15

facility’s inability to provide access to intralipid or supplies as well as adherence to
protocol. Limited access to the necessary supplies and knowledge deficit can lead to the
potential of providing a level of care not based on the latest evidence-based research.
Summary
Informal interviews were done with anesthesia administration and anesthesia
providers. After an analysis of the feedback, the data shows that many hospitals lack the
best practice clinical policy regarding the treatment for local anesthetic systemic toxicity.
A literature search was performed to analyze best practice guidelines for LAST
prevention and treatment. The available knowledge was synthesized in order to compile
a report of findings. This report of findings, along with the ASRA Checklist for
Treatment of LAST, was be presented to a panel of experts. An evaluation tool was used
to gather feedback on the presented data. The feedback guided revision of the policy
recommendations and develop an executive summary. The executive summary and
policy recommendation were then presented to the Chief CRNA for consideration of
implementation.
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CHAPTER III - RESULTS
This DNP project’s goal was to develop the best practice recommendation for the
treatment of local anesthetic systemic toxicity in a Mississippi hospital. A report of
findings was presented to the panel of experts, along with the ASRA’s checklist for
Treatment of LAST, an evaluation tool (ASRA, 2017) was used to determine the quality
of information presented, relevance to clinical practice, and potential for implementation
of the protocol. Additionally, each responding member of the expert panel was provided
the opportunity for further comments and suggestions in the form of the evaluation tool.
The panel of experts was comprised of the Chief CRNA, a pharmacist, a
registered nurse frequently involved with regional anesthesia, and a health policy expert.
Each member of this panel was chosen due to their familiarity with local anesthetic use,
availability of resources, and familiarity with policy development. The responses and
recommendations from this expert panel were reviewed and incorporated into an
executive summary that was presented to the Chief of the Anesthesia Department for
consideration, along with an accompanying educational module. The educational module
featured a pre- and post-test based on the information in the executive summary. The
project was intended that this module may be used in order to help with the
implementation of this best practice recommendation.
One member of the panel of experts was not able to be reached at the time of the
presentation. The responses are described in Table 1. All participants strongly agreed
that the information was presented clearly. They also strongly agreed that the
information was of high quality and relevant to clinical practice. Finally, all participants
reported that this best practice recommendation should be implemented. None of the
17

panel members had ever experienced an event of LAST, echoing findings in the review
of medical database literature that demonstrated the rarity of LAST occurrence. One
participant had an additional comment, “this hospital practices mock drills to familiarize
the staff with the location of needed supplies. The drill includes identifying the location
of the intralipid medication.” The recommendation was added to the executive summary.
Another recommendation was for an alternative to lipid infusion for hospitals that did not
have access to it. While the literature does not support an alternative at this time, the best
practice protocol that was recommended lists all the other steps that should be taken.
Without the use of intralipid, cardiopulmonary bypass may be needed, as resuscitation
may be prolonged (ASRA, 2018).
Summary
A best practice protocol was presented to a selected hospital-based panel of
experts, along with a treatment checklist that was developed by the ASRA. The expert
panel was then asked to complete an evaluation and provide any wanted comments or
recommendations. All the respondents strongly agreed that the information was clearly
presented, of high quality, and relevant to their practice. They also reported that the best
practice recommendation should be followed in their facility. The recommended idea of
mock drills to be prepared for a possible LAST event was an idea that is worthy of future
research.

.
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CHAPTER IV – DISCUSSION
Summary
This project was undertaken with the intent of decreasing the potential negative
consequences of LAST, while also increasing provider confidence in the ability to treat
such events. The literature review led to the discovery of a Checklist for Treatment of
LAST (ASRA, 2017). This checklist, along with supporting evidence, was used to
develop a best practice recommendation that was presented to a panel of experts. The
recommendation was presented to stakeholders at a USM affiliated hospital for input.
The feedback was then used to reinforce an Executive Summary (Appendix F) that was
sent to the panel upon completion.
Interpretation
The completed expert panel evaluations demonstrated the willingness to adopt
this best practice recommendation into use. The panel also provided potential areas of
improvement in the recommendation. These areas of recommended improvements
included mock drills to reinforce the recommendations. Additionally, one panelist
questioned the treatment options if lipids were not available, a concern that was
addressed in the executive summary. The panel’s responses and comments helped to
solidify the information presented in the executive summary.
Limitations
This project’s results were limited by the small sample size of the panel that was
presented and offered the opportunity to evaluate this project. Presenting these findings
to a larger audience would have provided the opportunity for more feedback and the
potential for a wider range of responses. While the review of literature featured
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information from a wide range of practices, the evaluation and expert panel were from
one hospital.
Conclusion
In conclusion, this doctoral project intended to improve the recognition and
treatment of LAST. From a review of the literature and informal interviews with
anesthesia providers, the data showed that a knowledge deficit exists surrounding the
treatment of LAST (Corcoran et al., 2006) (Appendix A). Potential negative
consequences of the failure to manage LAST include CNS toxicity, cardiac toxicity, and
death (Dillane & Finucane, 2009). A review of the literature was performed to identify
the best practice for the treatment of LAST. This information was compiled into a Report
of Findings that was then presented to a panel of experts. After presenting the
information, the panel of experts was asked to fill out a brief evaluation and provide any
comments they would like regarding the information provided. The panel unanimously
agreed that this best practice recommendation should be adopted in their clinical practice.
Their feedback was considered when developing the final executive summary, which was
presented to the anesthesia department along with an education module (Appendix-F) to
be used to improve knowledge of LAST in their department. Adoption of this best
practice recommendation has the potential to prevent the CNS toxicity, cardiac toxicity,
and deaths that may occur from improper recognition or treatment of LAST.
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APPENDIX B – Literature Matrix
Table A1.
Literature Matrix
Date of Publication

Author/Editor’s
Name

Type of Evidence

February 2010

Manavi, M. V.

Literature Review

October 2010

Varela, H.,
Burns, S. M.

Case Report
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Summary
Evidence suggests
that intralipid
should be readily
available in all
areas where local
anesthetics
injections are
performed and
should be used as
first-line treatment
for local anesthetic
toxicity. However,
the slow adoption
by providers may
endanger patients.
The increasing
number of case
reports involving
the successful use
of lipid emulsion
for the treatment of
local anesthetic
toxicity
demonstrates the
viability of
intralipid rescue as
a treatment
modality.

Table A1 (continued).

2017

American Society of
Regional Anesthesia
and Pain Medicine

2017

Barash, P. G.,
Cullen, B. F.,
Stoelting, R. K.,
Cahalan, M. K.,
Stock, C. M.,
Ortega, R.,
Holt, N. F.

August 2018

Nedialkov, A. M.,
Umadhay, T.,
Valdes, J. A.,
Campbell, Y.
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Practice Advisory

This practice
advisory provides
recommendations
pertaining to
prevention,
recognition, and
treatment of local
anesthetic systemic
toxicity.

Book Chapter

The use of local
anesthetics in the
form of neuraxial
and peripheral
anesthesia has the
potential to
improve patient
outcomes.

Best Practice and
Review of
Literature

Lipid rescue should
be readily available
and used as a firstline treatment for
local anesthetic
toxicity.

APPENDIX C – Report of Findings
LAST is a rare, but potentially fatal complication of administering local anesthetic
medications. LAST can quickly lead to the central nervous system and cardiac
compromise (Tetzlaff, 2000). This treatment differs in a few key areas from
conventional treatment of cardiac arrest, and therefore should be approached in a
different, more precise manner (Dillane & Finucane, 2009). For example, calcium
channel blockers and lidocaine are commonly used to treat the arrhythmias that arise in a
patient with cardiac compromise (Tetzlaff, 2000). However, these medications will lead
to a further decline in the patient with LAST. While the most effective treatment for
LAST has been well established, it was found through both reviews of literature and
survey of clinical preceptors that its rarity makes it a condition that most providers have
not encountered in clinical practice (Manavi, 2010; Nedialko et al., 2018). Additionally,
lipid emulsion use remains controversial among anesthesia providers although it has been
shown to drastically improve resuscitation following LAST (Nedialkov et al., 2018).
While the occurrence of LAST is rare, failure to treat or incorrect treatment of
LAST has the potential to result in patient injury or death (Barash et al., 2017; Sites et al.,
2012). From the review of the literature and informal interviews with anesthesia
providers, evidence was found that a knowledge deficit exists surrounding the treatment
of LAST (Corcoran et al., 2006). Potential negative consequences of the failure to
manage LAST include CNS toxicity, cardiac toxicity, and death (Dillane & Finucane,
2009). To address this gap in knowledge, a best practice recommendation was compiled
based on current evidence-based literature. The best practice recommendation was used
to create a treatment protocol that will be presented to anesthesia administration at a
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USM clinical affiliate hospital, along with an educational tool to facilitate dissemination
of the information.
The symptoms of LAST most frequently appear within the first few minutes of
injection of a local anesthetic. LAST most often occurs because of inadvertent
intravascular injection of local anesthetic or a higher than the therapeutic dose (Barash,
Cullen, & Stoelting, 2017). LAST symptoms occur in the central nervous system (CNS),
and/or the cardiovascular system. CNS symptoms can lead to respiratory depression,
coma, and eventually death. Cardiovascular symptoms are seen at a higher plasma
concentration than that which leads to CNS symptoms (Barash et al., 2017). While all
LA’s can cause hypotension, dysrhythmias and myocardial depression, more potent
agents, such as bupivacaine, ropivacaine, and levobupivacaine, are predisposed to
devastating outcomes such as cardiovascular collapse and complete heart block (Barash
et al., 2017). The exact mechanism that induces LAST is not clearly understood. To
quote Clinical Anesthesia (Barash, 2017), “The underlying pathophysiology responsible
for local anesthetic-induced cardiovascular collapse has not been fully established”
(Barash et al., 2017, p. 576). “Local anesthetics readily cross the blood-brain barrier and,
as a result, CNS toxicity can occur with systemic absorption or inadvertent intravascular
injections” (Barash et al., p. 575). The ease of diffusion across the blood-brain barrier
explains why in some cases, confusion and seizure activity precedes cardiovascular
symptoms. An especially dangerous drug that can present with cardiac symptoms is
bupivacaine. “Bupivacaine has an inherently greater affinity for binding resting and
inactivated cardiac sodium channels than lidocaine” (Barash et al., 2017 p. 577).
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Prevention of LAST
With the morbidity and mortality associated with LAST, every effort should be
made to prevent intravascular injection. No single intervention has been proven to
definitively eliminate the risk of LAST. Steps must be taken to avoid intravascular
injection and elevated blood concentration of the LA during the performance of the
regional technique. “Aspiration prior to injection of LA and the use of an intravascular
marker such as epinephrine reduces the likelihood of accidental intravascular injection to
a large extent” (Yaddnapudi, 2011, para. 2). The use of ultrasound-guided regional
anesthesia (UGRA) is a topic that is being explored. In theory, visualization of anatomic
structures and medication spread should reduce adverse outcomes associated with
regional anesthesia, including LAST. Due to the extreme rarity of this complication, a
statistically significant difference between nerve localization techniques, if indeed any
difference exists, will likely never be realized. However, there exists conflicting
evidence of whether UGRA results in a true reduction of LAST (Neal & Richard, 2010).
Evidence-Based Practice for Treatment of LAST
The American Society of Regional Anesthesia and Pain Medicine (ASRA)
updated the checklist for the management of LAST as recently as 2017. The
recommendations are described as “fundamentally different from conventional
cardiopulmonary resuscitation. Insofar as toxic cardiomyopathy differs from other
causes of CV collapse” (Neal & Barrington, 2017, para. 5). These guidelines recommend
early airway support over immediate cardiac support. This approach prioritizes the
prevention of hypercarbia and subsequent acidosis that can potentiate LAST. This article
states succinctly, “Successful treatment of LAST seeks to effectively moderate or reverse
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the mechanisms underlying the local anesthetic toxicity” (Neal & Barrington, 2017, para.
6). Data retrieved from rat studies reinforce the practice of administering small doses of
epinephrine when patient condition indicates (1mcg/kg or less) (Neal & Barrington,
2017). “Lipid therapy is recommended at the first sign of arrhythmia, prolonged seizures,
or rapid clinical deterioration of the patient” (Neal & Barrington, 2017, para. 8). The
exact mechanism of action for lipid therapy is unknown, but several theories exist. The
“lipid sink” theory states that the intravenous infusion of lipids creates a lipid
compartment in which the local anesthetic will be drawn, lowering the effective dose in
the aqueous plasma (Manavi, 2010). Other theories are related to the lipids increasing
available energy for cardiac muscle contraction (Nedialkov et al., 2018). Multiple case
reports demonstrate successful resuscitation following local anesthetic toxicity when
intralipid are used as early treatment (Valera & Burns, 2010). However, the use of
intralipid therapy remains controversial among anesthesia providers (Nedialkov et al.,
2018).
Existing Protocols
As stated before, in 2017 the American Society of Regional Anesthesia and Pain
Medicine (ASRA) updated the checklist for the treatment of local anesthetic system
toxicity treatment. Recommendations by The Association of Anaesthetists of Great
Britain and Ireland (2010) and Medscape (2019) echo the treatment described by the
ASRA. The initial treatment suggested is to stop or limit the insulating substance and get
help. If serious signs of LAST occur, consider limpid emulsion therapy immediately
(ASRA, 2017). Because of the gravity of a cardiovascular event from LAST, notifying
the nearest cardiopulmonary bypass team is also recommended. Providers are
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encouraged to ventilate with 100% oxygen, avoid hypoventilation, and insert advanced
airway if needed to control seizures. Benzodiazepines are the preferred method of seizure
management. Propofol is to be avoided due to its cardiac depressive properties. If the
patient weighs greater than 70 kilograms, a bolus of 100ml 20% lipid emulsion over a 23-minute period is recommended, followed by an infusion of 200-250 milliliters over 1520 minutes. For a patient, less than 70 kilograms a bolus of 1.5 milligrams-per-kilogram
(ideal body weight) lipid emulsion over 2-3 minutes, followed with an infusion of 0.25
milligram-per-kilogram is recommended. With a dosing limit of 12 milligrams-perkilogram, the total volume of lipid emulsion can approach 1 liter in a prolonged
resuscitation (ASRA, 2017). The Checklist for Treatment of Local Anesthetic Systemic
Toxicity is included at the end of this document.
Summary
There are many benefits of local anesthetic use, including decreased length of
hospital stay, increased pain control, decreased pulmonary complications, decreased
opioid use, and even increased survival rates in some cases (Baresh et. al., 2017). For
these reasons, the practice of regional anesthesia is on the rise. As with any anesthetic
procedure, there are always risks that must be acknowledged and properly managed.
True LAST is a rare event; thus, most anesthesia providers have not encountered it in
training or clinical practice. The rarity leads to a possible gap in provider understanding
of the proper treatment for LAST. Evidence shows that the use of checklists or protocols
can improve the selection of the appropriate treatment modality in uncommonly
encountered clinical events (Harrison et al., 2006; Ziewacz et al., 2011). Therefore, a
LAST treatment protocol is presented in order to ensure an effective treatment in the
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event of LAST. The protocol will be recommended to be readily available in all
operative environments where local anesthetics are to be administered.
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Checklist for Treatment of Local Anesthetic Systemic Toxicity (LAST)
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(ASRA, 2017).
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APPENDIX D – Evaluation Tool
Please circle your answers to the following questions.
1. This best practice recommendation was presented clearly.
Strongly Disagree

Disagree

Neutral

Agree

Strongly Agree

Agree

Strongly Agree

Agree

Strongly Agree

2. The presented information is of high quality.
Strongly Disagree

Disagree

Neutral

3. The information is relevant to clinical practice.
Strongly Disagree

Disagree

Neutral

4. Do you believe that this best practice recommendation should be implemented in your
facility?

Yes

No

5. If you answered “No” to question 4, please briefly explain your answer.
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
6. Please provide any additional comments and/or suggestions below.
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
_______________________________________________________________________
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APPENDIX E – DNP Essentials
Table A2.
DNP Essentials
DNP Essentials
Essential One: Scientific Underpinnings
for practice
Essential Two: Organizational and
Systems Leadership for Quality
Improvement and Systems Thinking
Essential Three: Clinical Scholarship and
Analytical Methods for Evidence-Based
Practice
Essential Four: Information
Systems/Technology and Patient Care
Technology for the Improvement and
Transformation of Health Care

Clinical Implications
Research of evidence-based protocols to
manage an anesthesia-crisis.
Involving department leaders in the
development of a cognitive aid to
improve patient care.
Synthesis and analysis of available
knowledge for the treatment of local
anesthetic systemic toxicity.
Introduction of a cognitive aid to guide to
improve patient outcomes from a
potential anesthetic crisis.
This project advocates for the
implementation of a cognitive aid for use
in identifying and treating local anesthetic
systemic toxicity.
Communication with an interdisciplinary
panel of experts on proposed protocol and
seeking feedback on how to implement in
a real-world situation.
Potential prevention of negative sequelae
by guiding the correct treatment of a
LAST event.
Interpreting available knowledge to
determine best practice, identifying a
relevant guideline, and assessing the
potential implementation of said evidence
into clinical practice.

Essential Five: Health Care Policy for
Advocacy in Health Care.
Essential Six: Interprofessional
Collaboration for Improving Patient and
Population Health Outcomes
Essential Seven: Clinical Prevention and
Population Health for Improving the
Nation’s health
Essential Eight: Advanced Nursing
Practice
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APPENDIX F – Executive Summary

EXECUTIVE SUMMARY OF DEVELOPING A LOCAL ANESTHETIC SYSTEMIC
TOXICITY PROTOCOL IN A MISSISSIPPI HOSPITAL

by
James Dearman and Terry Tieman
The University of Southern Mississippi
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This document is an executive summary of full report Developing a LAST
Protocol in a Mississippi Hospital. The student registered nurse anesthetists performed a
literature review regarding the best practice recommendations for the treatment of LAST.
These findings, along with a potential protocol for using best practice recommendations,
were presented to a panel of experts to determine suitability for these recommendations
in clinical practice.
Report of Findings
Local anesthetic systemic toxicity (LAST) is a rare, but potentially fatal
complication of administering local anesthetic medications. LAST can quickly lead to
the central nervous system and cardiac compromise (Tetzlaff, 2000). Its treatment differs
in a few key areas from conventional treatment of cardiac arrest, and therefore should be
approached in a different, more precise manner (Dillane & Finucane, 2009). For
example, calcium channel blockers and lidocaine are commonly used to treat the
arrhythmias that arise in a patient with cardiac compromise (Tetzlaff, 2000). However,
these medications will lead to a further decline in the patient with LAST. While the most
effective treatment for LAST has been well established, it was found through both
reviews of literature and survey of clinical preceptors that its rarity makes it a condition
that most providers have not encountered in clinical practice (Manavi, 2010; Nedialkov et
al., 2018). Additionally, although lipid emulsion has been shown to drastically improve
resuscitation following local anesthetic systemic toxicity, its use remains controversial
among anesthesia providers (Nedialkov et al., 2018).
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While the occurrence of LAST is rare, failure to treat or incorrect treatment of
LAST has the potential to result in patient injury or death (Barash et al., 2017; Sites et al.,
2012). With the recent movement towards reducing opioid use, as well as, the increasing
use of ultrasound for peripheral nerve blocks, local anesthetics use is on the rise. From
the review of the literature and informal interviews with anesthesia providers, the authors
found that a knowledge deficit exists surrounding the treatment of LAST (Corcoran et al.,
2006). Potential negative consequences of the failure to manage LAST include CNS
toxicity, cardiac toxicity, and death (Dillane & Finucane, 2009). To address this gap in
knowledge, a best practice recommendation was compiled based on current evidencebased literature. The best practice recommendation was used to create a treatment
protocol that will be presented to anesthesia administration at a USM clinical affiliate
hospital, along with an educational tool to facilitate dissemination of the information.
The symptoms of LAST almost always appear within the first few minutes of
injection of a local anesthetic. LAST most often occurs because of inadvertent
intravascular injection of local anesthetic or a higher than the therapeutic dose (Barash et
al., 2017). LAST symptoms occur in the central nervous system (CNS), and/or the
cardiovascular system. CNS symptoms can lead to respiratory depression, coma, and
eventually death. Cardiovascular symptoms are seen at a higher plasma concentration
than that which leads to CNS symptoms (Barash et al., 2017). While all LA’s can cause
hypotension, dysrhythmias and myocardial depression, more potent agents, such as
bupivacaine, ropivacaine, and levobupivacaine, are predisposed to devastating outcomes
such as cardiovascular collapse and complete heart block (Barash et al., 2017). The exact
mechanism that induces LAST is not clearly understood. To quote Clinical Anesthesia
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(Barash et al., 2017). “The underlying pathophysiology responsible for local anestheticinduced cardiovascular collapse has not been fully established” (Barash et al., 2017, p.
576). “Local anesthetics readily cross the blood-brain barrier and, as a result, CNS
toxicity can occur with systemic absorption or inadvertent intravascular injections
(Barash et al., 2017). This action explains why in some cases, confusion and seizure
activity precedes cardiovascular symptoms. An especially dangerous drug that can
present with cardiac symptoms is bupivacaine. “Bupivacaine has an inherently greater
affinity for binding resting and inactivated cardiac sodium channels than lidocaine”
(Barash et al., 2017, p. 577).
Prevention of LAST
With the morbidity and mortality associated with LAST, every effort should be
made to prevent intravascular injection. No single intervention has been proven to
definitively eliminate the risk of LAST. Steps must be taken to avoid intravascular
injection and elevated blood concentration of the LA during the performance of the
regional technique. “Aspiration before injection of LA and the use of an intravascular
marker such as epinephrine reduces the likelihood of accidental intravascular injection to
a large extent.” (Yaddnapudi, 2011, para. 2). The use of ultrasound-guided regional
anesthesia (UGRA) is a topic that is being explored. In theory, visualization of anatomic
structures and medication spread should reduce adverse outcomes associated with
regional anesthesia, including LAST. Due to the extreme rarity of this complication, a
statistically significant difference between nerve localization techniques, if indeed any
difference exists, will likely never be realized. There appears to be conflicting evidence
of whether UGRA results in a true reduction of LAST (Neal & Richard, 2010).
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Evidence-Based Practice for Treatment of LAST
The American Society of Regional Anesthesia and Pain Medicine (ASRA)
updated the checklist for the management of LAST as recently as 2017. The
recommendations are described as “fundamentally different from conventional
cardiopulmonary resuscitation. Insofar as toxic cardiomyopathy differs from other causes
of CV collapse” (Neal & Barrington, 2017, para. 5). These guidelines recommend early
airway support over immediate cardiac support. This approach prioritizes the prevention
of hypercarbia and subsequent acidosis that can potentiate LAST. This article states
succinctly, “Successful treatment of LAST seeks to effectively moderate or reverse the
mechanisms underlying the local anesthetic toxicity” (Neal & Barrington, 2017, para. 6).
Data retrieved from rat studies reinforce the practice of administering small doses of
epinephrine when patient condition indicates (1mcg/kg or less) (Barrington, 2017).
“Lipid therapy is recommended at the first sign of arrhythmia, prolonged seizures, or
rapid clinical deterioration of the patient” (Neal & Barrington, 2017, para. 8). The exact
mechanism of action for lipid therapy is unknown, but several theories exist. The “lipid
sink” theory states that the intravenous infusion of lipids creates a lipid compartment in
which the local anesthetic will be drawn, lowering the effective dose in the aqueous
plasma (Manavi, 2010). Other theories are related to the lipids increasing available
energy for cardiac muscle contraction (Nedialkov et al., 2018). Multiple case reports
demonstrate successful resuscitation following local anesthetic toxicity when intralipid is
used as early treatment (Valera & Burns, 2010). However, the use of intralipid therapy
remains controversial among anesthesia providers (Nedialkov et al., 2018).
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Existing Protocols
As stated previously, in 2017 the American Society of Regional Anesthesia and
Pain Medicine (ASRA) updated the checklist for the treatment of local anesthetic system
toxicity treatment. Recommendations by The Association of Anaesthetists of Great
Britain and Ireland (2010) and Medscape (2019) echo the treatment described by the
ASRA. The suggested initial intervention is to stop the injecting the local anesthetic and
get help. If serious signs of LAST occur, consider lipid emulsion therapy immediately
(ASRA, 2017, p. 1). Because of the gravity of a cardiovascular event from LAST,
notifying the nearest cardiopulmonary bypass team is also recommended. Providers are
encouraged to ventilate with 100% oxygen, avoid hypoventilation, and insert advanced
airway if needed to control seizures. Benzodiazepines are the preferred method of
seizure management. Propofol is to be avoided due to its cardiac depressive properties. If
the patient weighs greater than 70 kg, a bolus of 100 ml 20% lipid emulsion over a 2-3minute time period is recommended, followed by an infusion of 200-250 ml over 15-20
minutes. For a person less than 70 kg, a bolus of 1.5 ml/kg (ideal body weight) lipid
emulsion over 2-3-minutes, followed with an infusion of 0.25 ml/kg is recommended.
With a dosing limit of 12 mL/kg, the total volume of lipid emulsion can approach 1 L in a
prolonged resuscitation (ASRA, 2017). The Checklist for Treatment of Local Anesthetic
Systemic Toxicity is included at the end of this document.
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Summary
Literature shows many benefits of local anesthetic use, including decreased length
of hospital stay, increased pain control, decreased pulmonary complications, decreased
opioid use, and even increased survival rates in some cases (Baresh et al., 2017). For
these reasons, its practice is on the rise. As with any anesthetic procedure, there are
always risks that must be acknowledged and properly managed. True local anesthetic
systemic toxicity is a rare event; thus, most anesthesia providers have not encountered it
in training or clinical practice. This leads to a possible gap in provider understanding of
the proper treatment for LAST. Evidence shows that the use of checklists or protocols
can improve the selection of the appropriate treatment modality in uncommonly
encountered clinical events (Harrison, Manser, Howard, & Gaba, 2006; Ziewacz,
Arriaga, Bader et al., 2011). Therefore, a local anesthetic systemic toxicity treatment
protocol is presented in order to ensure an effective treatment in the event of LAST. It
was recommended that this protocol be readily available in all operative environments
where local anesthetics are to be administered. The authors also recommend that the preand post-test be used, as well as, mock drills in order to train the anesthesia staff on the
proper treatment of LAST. Worth noting is the fact that in the event that lipids are not
available, cardiopulmonary bypass may be needed, as resuscitation may be prolonged
(ASRA, 2018).
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Checklist for Treatment of Local Anesthetic Systemic Toxicity (LAST)
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(ASRA, 2017).

45

References
American Society of Regional Anesthesia and Pain Medicine (ASRA). (2017). Checklist
for Treatment of Local Anesthetic Toxicity (LAST). Retrieved from
https://www.asra.com/content/documents/asra_last_checklist_2018.pdf
Association of Anaesthetists of Great Britain and Ireland. (2010). AAGBI Safety
Guideline. Retrieved from
https://www.aagbi.org/sites/default/files/la_toxicity_2010_0.pdf
Barash, P. G., Cullen, B. F., Stoelting, R. K., Cahalan, M. K., Stock, M. C., Ortega, R., ...
Holt, N. F. (eds.). (2017). Neuraxial anesthesia. Clinical Anesthesia (8th ed.).
Philadelphia, PA: Lippincott.
Corcoran, W., Butterworth, J., Weller, .R.S. et al., (2006). Local anesthetic induced
cardiac toxicity: a survey of contemporary practice strategies among academic
anesthesiology departments. Anesthesia & Analgesia, 103(5), 1322-1326.
Cousins, M. J., Carr, D. B., Horlocker, T. T., & Bridenbaugh, P. O. (Eds.). (2009).
Neuronal blockade: Impact on outcome. Neuronal blockade in clinical anesthesia
and pain medicine (4th ed., Ch. 7). Philadelphia, PA: Lippincott.
Dillane, D., & Finucane, B. T. (2009). Local anesthetic systemic toxicity. Canadian
Journal of Anesthesia, 57, 368–380. https://doi.org/10.1007/s12630-010-9275
Harrison, T.K., Manser, Howard, S.K., & Gaba, D.M. (2006). Use of cognitive aids in a
simulated anesthetic crisis. Anesthesia & Analgesia, 103, 551-556.
Lin, Y., & Liu, S. S. (2017). Local anesthetics. In P. G. Barash, B. F., Cullen, R. K.
Stoelting, M. K., Cahalan, M. C., Stock, R., Ortega, N. F., Holt (Eds.), Clinical
Anesthesia (8th ed., Ch. 22). Philadelphia, PA: Lippincott.
46

Leotsakos, A., Zheng, H., & Croteau, R. (2014, April 1, 2014). Standardization in patient
safety: the WHO high 5s project. International Journal for Quality in Health
Care, 26. Retrieved from
https://academic.oup.com/intqhc/article/26/2/109/1803803
Manavi, M. V. (2010, February). Lipid Infusion as a Treatment for Local Anesthetic
Toxicity: A Literature Review. AANA Journal Course, vol. 78, no. 1.
Medscape. (2019). Local Anesthetic Toxicity Treatment & Management. Retrieved from
https://emedicine.medscape.com/article/1844551-treatment
Mississippi State Department of Health. (2018). 2018 Mississippi State Health Plan.
Retrieved fromhttps://msdh.ms.gov/msdhsite/index.cfm/29,7749,184,pdf/2nd_ed
_state_health_plan.pdf
Neal, J., & Richard, B. (2010). The ASRA evidence-based medicine assessment of
ultrasound-guided regional anesthesia and pain medicine: executive study.
Regional Anesthesia & Pain Medicine. Retrieved from
https://journals.lww.com/rapm/Fulltext/2010/03001/The_ASRA_Evidence_Based
_Medicine_Assessment_of.1.aspx
Nedialkov, A., Umadhay, T., Valdes, J., & Campbell, Y. (2018, August). Intravenous Fat
Emulsion for Treatment of Local Anesthetic Systemic Toxicity: Best Practice and
Review of the Literature, AANA Journal Online, 86(4), 290-97.
Sites, B., Taenzer, A., Herrick, M., & Gilloon, C. (2012). Incidence of local anesthetic
systemic toxicity and postoperative neurologic symptoms associated with 12,668

47

ultrasound-guided nerve blocks: an analysis from a prospective clinical registry.
Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22705953
Tetzlaff, J. E. (2000). The pharmacology of local anesthetics. Anesthesiology Clinics of
North America, 18, 217-233. https://doi.org/10.1016/S0889-8537
Valencia, M. I., & Silva, J. V. (2013). Protocol and importance of using the kit for local
anesthetic toxicity. Retrieved from
https://www.sciencedirect.com/science/article/pii/S225620871300059X#fig001
Valera, H., & Burns, S. (2010, October). Use of Lipid Emulsions for Treatment of Local
Anesthetic Toxicity: A Case report, AANA Journal, 78(5).
Yaddnapudi, S. (2011, October 27). Prevention of local anesthetic systemic toxicity.
NCBI. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214545/
Ziewacz, J.E., Arriaga, A.F., Bader, A.M. et al. (2011). Crisis checklists for the operating
room: Development and Pilot testing. Journal of the American College of
Surgeons, 213, 212-219. Retrieved from:
https://doi.org/10.1016/j.jamcollsurg.2011.04.031

48

APPENDIX G – Pre- and Post-Test Evaluations
Pre-Test Evaluation
1. Management of a LAST event can be managed with standard ACLS protocols for
optimal outcomes? True or False
2. The first line mediation for treatment of LAST induced seizures is. A. Propofol B.
Intralipid C. Phenytoin D. Benzodiazepines
3. Which medication is proven to be the most beneficial in the treatment of LAST at
the first sign of cardiac arrhythmia, prolonged seizures, or rapid clinical
deterioration of the patient? A. Amiodarone B. Epinephrine C. Lidocaine D.
Intralipid
4. The Initial dose of intralipid for a patient greater than 70 kg is? A. 50 ml B. 200
ml C. 100 ml D. 25 ml

49

Post Test Evaluation
1. Management of a LAST event can be managed with standard ACLS protocols for
optimal outcomes? True or False
2. The first line mediation for treatment of LAST induced seizures is. A. Propofol B.
Intralipid C. Phenytoin D. Benzodiazepines
3. Which medication is proven to be the most beneficial in the treatment of LAST at
the first sign of cardiac arrhythmia, prolonged seizures, or rapid clinical
deterioration of the patient? A. Amiodarone B. Epinephrine C. Lidocaine D.
Intralipid
4. The Initial dose of intralipid for a patient greater than 70 kg is? A. 50 ml B. 200
ml C. 100 ml D. 25 ml
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Answer Key:
1. False
2. D. Benzodiazepines
3. D. Intralipid
4. C. 100 ml
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